|

Axitinib plus Toripalimab Clinical Trials

1 actively recruiting trial

Also known as: nephrectomy

Pipeline

Phase 3: 1

Top Sponsors

  • ZHOU FANGJIAN1

Indications

  • Neoadjuvant1
  • Renal Cell Carcinoma1
  • Cancer1

Other1 trial

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.